Rolof G.P. Gijtenbeek

RSV infection among children born moderately preterm in a community-based cohort

Rolof G.P. Gijtenbeek, Jorien M. Kerstjens, Sijmen A. Reijneveld et al. · European Journal of Pediatrics · 2014 · 54 citations

Medicine, Infectious Diseases, Pediatrics +14

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study

Rolof G.P. Gijtenbeek, Ronald Damhuis, Anthonie J. van der Wekken et al. · The Lancet Regional Health - Europe · 2023 · 52 citations · Full text

Medicine, Oncology, Pharmacology +16

Nationwide Real-world Cohort Study of First-line Tyrosine Kinase Inhibitor Treatment in Epidermal Growth Factor Receptor-mutated Non–small-cell Lung Cancer

Rolof G.P. Gijtenbeek, Ronald Damhuis, Harry J.M. Groen et al. · Clinical Lung Cancer · 2020 · 17 citations · Full text

Medicine, Oncology, Pharmacology +11

Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC

Jiacong Wei, Pei Meng, Miente Martijn Terpstra et al. · Targeted Oncology · 2021 · 14 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI)<i>versus</i>intercalated TKI with chemotherapy for<i>EGFR</i>-mutated nonsmall cell lung cancer

Rolof G.P. Gijtenbeek, Vincent van der Noort, Joachim G.J.V. Aerts et al. · ERJ Open Research · 2022 · 10 citations · Full text

Medicine, Oncology, Pharmacology +17